Migraine: Preventive treatment

Cephalalgia

Volumn 22, Issue 7, 2002, Pages 491-512

  Silberstein, Stephen D ^a   Goadsby, P J ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Migraine; Prevention; Prophylaxis; Treatment

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; CLOMIPRAMINE; DOXEPIN; FLUNARIZINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; MAGNESIUM; METHYLERGOMETRINE MALEATE; METHYSERGIDE; METOPROLOL; MONOAMINE OXIDASE INHIBITOR; NADOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PROPRANOLOL; RIBOFLAVIN; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TANACETUM PARTHENIUM EXTRACT; TIMOLOL; TOPIRAMATE; TRICARBOXYLIC ACID; UNINDEXED DRUG; VERAPAMIL; ANALGESIC AGENT;

ABDOMINAL PAIN; AGEUSIA; ALOPECIA; ANALGESIA; ANOREXIA; ANXIETY DISORDER; ASTHENIA; BRADYCARDIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLAUDICATION; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG HALF LIFE; DRUG MECHANISM; EJACULATION DISORDER; EPIGASTRIC PAIN; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FLUSHING; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HALLUCINATION; HEADACHE; HEART PALPITATION; HEMIPLEGIA; HUMAN; HYPERHIDROSIS; HYPERTENSIVE CRISIS; HYPOMANIA; IMPOTENCE; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; JOINT STIFFNESS; LASSITUDE; LEG CRAMP; LETHARGY; LIBIDO DISORDER; LONG TERM CARE; MEMORY DISORDER; MENTAL DISEASE; MIGRAINE; MOUTH INFLAMMATION; MOUTH ULCER; MUSCLE DISEASE; MYALGIA; NAUSEA; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PREGNANCY; REVIEW; SIDE EFFECT; SLEEP DISORDER; TACHYCARDIA; TENSION HEADACHE; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREMOR; URINE RETENTION; VASOMOTOR DISORDER; VERTIGO; VISUAL DISORDER; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; METHODOLOGY; STATISTICS;

ANALGESICS; CLINICAL TRIALS; HUMANS; MIGRAINE DISORDERS;

EID: 0036727675     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2002.00386.x     Document Type: Review

References (282)

1. Silberstein SD, Lipton RB, Goadsby PJ. Headache in clinical practice. Oxford: Isis Medical Media Ltd., 1998.
2. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia, and facial pain. Cephalalgia 1988; 8:1-96.
3. Lipton RB, Silberstein SD. Why study the comorbidity of migraine? Neurology 1994; 44:4-5.
4. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. (2000) Evidenced-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. http//www.neurology.org
5. Silberstein SD. Migraine and pregnancy. Neurologic Clinics 1997; 15:209-31.
6. Tfelt-Hansen P. Prioritizing acute pharmacotherapy of migraine. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches, 2nd edn. New York: Lippincott Williams & Wilkins, 2000:453-6.
7. Rabkin R, Stables DP, Levin NW, Suzman M. The prophylactic value of propranolol in angina pectoris. Am J Cardiol 1966; 18:370-83.
8. Weber RB, Reinmuth OM. The treatment of migraine with propranolol. Neurology 1972; 22:366-9.
9. Diamond S, Medina JL. Double-blind study of propranolol for migraine prophylaxis. Headache 1976; 16:24-27.
10. Gray RN, Goslin RE, McCrory DC, Eberlein K, Tulsky J, Hasselblad V. Drug treatments for the prevention of migraine headache. Prepared for the Agency for Health Care Policy and Research, Contract no. 290-94-2025 (Technical Review 2.3, February). Available from the National Technical Information Service, Accession no. 127953; 1999.
11. Silberstein SD. Practice parameter - evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology for the United States Headache Consortium. Neurology 2000; 55:754-62.
12. Andersson K, Vinge E. Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs 1990; 39:355-73.
13. Holroyd KA, Penzien DB, Coordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991; 31:333-40.
14. Mathew NT. Prophylaxis of migraine and mixed headache. A randomized controlled study. Headache 1981; 21:105-9.
15. Langohr HD, Gerber WD, Koletzki E, Mayer K, Schroth G. Clomipramine and metoprolol in migraine prophylaxis: a double-blind crossover study. Headache 1985; 25:107-13.
16. Andersson PG, Dahl S, Hansen JH, Hansen PE, Hedman C, Kristensen TN, de Fine Olivarius B. Prophylactic treatment of classical and nonclassical migraine with metoprolol: a comparison with placebo. Cephalalgia 1983; 3:207-12.
17. Kangasniemi P, Andersen AR, Andersson PG, Gilhus ME, Hedman C, Hultgren M et al. Classic migraine: effective prophylaxis with metoprolol. Cephalalgia 1987; 7:231-8.
18. Steiner TJ, Joseph R, Hedman C, Rose FC. Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging followup. Headache 1988; 28:15-23.
19. Steardo L, Bonuso S, DiStasio E, Marano E. Selective and nonselective beta-blockers: are both effective in prophylaxis of migraine? A clinical trial versus methysergide. Acta Neurol 1982; 4:196-204.
20. Gerber WG, Diener H, Scholz E, Niederberger U. Responders and nonresponders to metoprolol, propranolol and nifedipine treatment in migraine prophylaxis: a dose-range study based on time-series analysis. Cephalalgia 1991; 11:37-45.
21. Olsson JE, Behring HC, Forssman B, Hedman C, Hedman G, Johansson F et al. Metoprolol and propranolol m migraine prophylaxis: a double-blind multicenter study. Acta Neurol Scand 1984; 70:160-80.
22. Grotemeyer KH, Scharafinski HW, Schlake HP, Husstedt IW. Acetylsalicylic acid vs metoprolol in migraine prophylaxis: a double-blind crossover study. Headache 1990; 30:639-41.
23. Sorensen PS, Larsen BH, Rasmussen MJ, Kinge E, Iversen H, Alslev T et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 1991; 10:657.
24. Vilming S, Standnes B, Hedman C. Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine: a double-blind investigation. Cephalalgia 1985; 5:17-23.
25. Stensrud P, Sjaastad O. Short-term trial of propranolol in racemic form (Inderal), d-propranolol and placebo in migraine. Acta Neurol Scand 1976; 53:229-32.
26. Briggs RS, Millac PA. Timolol in migraine prophylaxis. Headache 1979; 19:379-81.
27. Stellar S, Ahrens SP, Meibohm AR, Reines SA. Migraine prevention with timolol: a double-blind crossover study. JAMA 1984; 252:2576-80.
28. Forssman B, Lindblad CJ, Zbornikova V. Atenolol for migraine prophylaxis. Headache 1983; 23:188-90.
29. Johannsson V, Nilsson LR, Widelius T, Javerfalk T, Hellman P, Akesson JA et al. Atenolol in migraine prophylaxis: a double-blind crossover multicenter study. Headache 1987; 27:372-4.
30. Stensrud P, Sjaastad O. Clinical trial of a new antibradykinin, antiinflammatory drug, ketoprofen (19.583 r.p.) in migraine prophylaxis. Headache 1974; 14:96-100.
31. Tobita M, Hino M, Ichikawa N, Takase S, Ogawa A. A case of hemiplegic migraine treated with flunarizine. Headache 1987; 27:487-8.
32. Freitag FG, Diamond S. Nadolol and placebo comparison study in the prophylactic treatment of migraine. J Am Osteopath Assoc 1984; 84:343-7.
33. Olerud B, Gustavsson CL, Furberg B. Nadolol and propranolol in migraine management. Headache 1986; 26:490-3.
34. Ryan RE, Sudilovsky A. Nadolol: its use in the prophylactic treatment of migraine. Headache 1983; 23:26-31.
35. Ryan RE. Comparative study of nadolol and propranolol in prophylactic treatment of migraine. Am Heart J 1984; 108:1156-9.
36. Sudilovsky A, Stern MA, Meyer JH. Nadolol: the benefits of an adequate trial duration in the prophylaxis of migraine. Headache 1986; 26:325.
37. Ekbom K, Lundberg PO. Clinical trial of LB-56 (d. 1-4-(2-hydroxy-3-isopropylaminopropoxy) indol): an adrenergic beta-receptor blocking agent in migraine prophylaxis. Headache 1972; 12:15-17.
38. Ekbom K, Zetterman M. Oxprenolol in the treatment of migraine. Acta Neurol Scand 1977; 56:181-4.
39. Nanda RN, Johnson RH, Gray J, Keugh HJ, Melville ID. A double-blind trial of acebutolol for migraine prophylaxis. Headache 1978; 18:379-81.
40. Ekbom K. Alprenolol for migraine prophylaxis. Headache 1994; 34:476-8.
41. Sjaastad O, Stensrud P. Clinical trial of a beta-receptor blocking agent (LB46) in migraine prophylaxis. Acta Neurol Scand 1972; 48:124-8.
42. Fanchamps A. Why do not all beta-blockers prevent migraine? Headache 1985; 25:61-62.
43. Shanks RG. A review of the relationship between beta-adrenoreceptor antagonists and their action in migraine. In: Rose FC, editor. Advances in headache research. London: John Libbey, 1987:161-6.
44. Wideroe TE, Vigander T. Propranolol in the treatment of migraine. Br Med J 1974; 2:699-701.
45. Kuritzky A, Hering R. Prophylactic treatment of migraine with long acting propranolol: a comparison with placebo. Cephalalgia 1987; 7:457-8.
46. Solomon GD. Verapamil and propranolol in migraine prophylaxis: a double-blind crossover study. Headache 1986; 26:325.
47. Ablad B, Dahlof C. Migraine and β-blockade: modulation of sympathetic neurotransmission. Cephalalgia 1986; 6:7-13.
48. Koella WP. CNS-related (side-)effects of β-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol 1985; 28:55-63.
49. Silberstein SD, Silberstein MM. New concepts in the pathogenesis of headache. Part II. Pain Mgt 1990; 3:334-42.
50. Schoenen J, Maertens de Noordout A, Timsit-Bertheir M, Timisit M. Contingent negative variation and efficacy of β-blocking agents in migraine. Cephalalgia 1986; 6:231-3.
51. Stoica E, Enulescu O. Propranolol corrects the abnormal catecholamine response to light during migraine. Eur Neurol 1990; 30:19-22.
52. Featherstone HJ. Low dose propranolol therapy for aborting acute migraine. West J Med 1983; 138:416-7.
53. Rosen JA. Observations on the efficacy of propranolol for the prophylaxis of migraine. Ann Neurol 1983; 13:92-93.
54. Diamond S, Kudrow L, Stevens J, Shapiro DB. Long-term study of propranolol in the treatment of migraine. Headache 1982; 22:268-71.
55. Dahlof C. No clear-cut long-term prophylactic effect of one month of treatment with propranolol in migraineurs. Cephalalgia 1987; 7:459-60.
56. Frishman WH. Beta adrenergic blocker withdrawal. Am J Cardiol 1987; 59:32F.
57. Pradalier A, Serratrice G, Collard M, Hirsch E, Feve J, Masson M et al. Long-acting propranolol on migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia 1989; 9:247-53.
58. Diamond S, Solomon GD, Freitag FG, Mehta ND. Long-acting propranolol in the prophylaxis of migraine. Headache 1987; 27:70-72.
59. Cortelli P, Sacquegna T, Albani F, Baldrati A, D'Alessandro R, Baruzzi A, Lugaresi F. Propranolol plasma levels and relief of migraine. Arch Neurol 1985; 42:46-48.
60. Sudilovsky A, Elkind AH, Ryan RE, Saper JR, Stern MA, Meyer JH. Comparative efficacy of nadolol and propranolol in the management of migraine. Headache 1987; 27:421-6.
61. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992; 32:101-4.
62. Andersson PG, Petersen EN. Propranolol and femoxetine, a 5HT-uptake inhibitor, in migraine prophylaxis: a double-blind crossover study. Acta Neurol Scand 1981; 64:280-8.
63. Bonuso S, DiStasio E, Barone P, Steardo L. Timed-release dihydroergotamine in the prophylaxis of mixed headache: a study versus amitriptyline. Cephalalgia 1983; 3:175-8.
64. Couch JR, Hassanein RS. Migraine and depression: effect of amitriptyline prophylaxis. Trans Am Neurol Assoc 1976; 101:234-7.
65. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979; 36:695-9.
66. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry 1973; 36:684-90.
67. Jacobs H. A trial of opipramol in the treatment of migraine. J Neurol Neurosurg Psychiatr 1972; 35:500-4.
68. Kangasniemi PJ, Nyrke T, Lang AH, Petersen E. Femoxetine - a new 5HT uptake inhibitor - and propranolol in the prophylactic treatment of migraine. Acta Neurol Scand 1983; 68:262-7.
69. Monro P, Swade C, Coppen A. Mianserin in the prophylaxis of migraine: a double-blind study. Acta Psychiatr Scand 1985; 72:98-103.
70. Noone JF. Clomipramine in the prevention of migraine. J Int Med Res 1980; 8:49-52.
71. Saper JR, Silberstein SD, Lake AE, Winters ME. Double-blind trial of fiuoxetine: chronic daily headache and migraine. Headache 1994; 34:497-502.
72. Zeeberg I, Orholm M, Nielsen JD, Honor PL, Larsen JJ. Femoxetine in the prophylaxis of migraine: a randomized comparison with placebo. Acta Neurol Scand 1981; 64:452-9.
73. Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol 1987; 44:486-9.
74. Orholm M, Honor PF, Zeeberg I. A randomized general practice group-comparative study of femoxetine and placebo in the prophylaxis of migraine. Acta Neurol Scand 1986; 74:235-9.
75. Bank J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 1994; 34:476-8.
76. Heninger GR, Charney DS. Mechanism of action of antidepressant treatments: implications for the etiology and treatment of depressive disorders. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:535-44.
77. Taiwo YO, Levine JD. Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia. Neurosci 1991; 44:131-5.
78. Sawynok J, Reid A, Poon A. Peripheral antinociceptive effect of an adenosine kinase inhibitor, with augmentation by an adenosine deaminase inhibitor, in the rat formalin test. Pain 1998; 74:75-81.
79. Sawynok J, Reid AR, Esser MJ. Peripheral antinociceptive action of amitriptyline in the rat formalin test: involvement of adenosine. Pain 1999; 80:45-55.
80. Couch JR, Ziegler D, Hassanein R. Amitriptyline in the prophylaxis of migraine: effectiveness and relationship of antimigraine and antidepressant effects. Neurology 1976; 26:121-7.
81. Panerai AE, Monza G, Movilia P, Bianchi M, Francussi BM, Tiengo M. A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol Scand 1990; 82:34-38.
82. Kishore-Kumar R, Max MB, Schafer SC, Gaughan AM, Smoller B, Gracely RH, Dubner R. Desipramine relieves post-herpetic neuralgia. Clin Pharmacol Ther 1990; 47:305-12.
83. Feinmann C. Pain relief by antidepressants: possible modes of action. Pain 1985; 23:1-8.
84. Richelson E. Antidepressants and brain neurochemistry. Mayo Clin Proc 1990; 65:1227-36.
85. Richardson JW, Richelson E. Antidepressants: a clinical update for medical practitioners. Mayo Clin Proc 1984; 59:330-7.
86. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. The pharmacological basis of therapeutics, 8th edn. New York: Pergamon, 1990:383-435.
87. Abramowicz M. Fluoxetine (Prozac) revisited (letter). Drugs Ther 1990; 32:83-85.
88. Barnhart ER. Physicians' desk reference, 45th edn. Oradell: Medical Economics Inc, 1991.
89. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K. Fluoxetine added to nonMAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989; 50:447-9.
90. Steiner TJ, Ahmed F, Findley LJ, MacGregor EA, Wilkinson M. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 1998; 18:283-6.
91. Markley HG, Gasser PA, Markley ME, Pratt SM. Fluoxetine in prophylaxis of migraine: clinical experience. Cephalalgia 1991; 11:164-5.
92. Solomon G, Kunkel R. Effects of fluoxetine on premenstrual syndrome in chronic headache sufferers. Headache 1990; 30:301.
93. d'Amato CC, Pizza V, Marmolo T, Giordano E, Alfano V, Nasta A. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 1999; 39:716-9.
94. Anthony M, Lance JW. Monoamine oxidase inhibition in the treatment of migraine. Arch Neurol 1969; 21:263-8.
95. Raskin N, Raskin N, editors. Headache, 2nd edn. New York: Churchill Livingstone, 1988:229-30.
96. Saper JR, Silberstein SD, Gordon CD, Hamel RL. Handbook of headache management. Baltimore: Williams & Wilkins, 1993.
97. Lance JW. The pharmacotherapy of migraine. Med J Aust 1986; 144:85-88.
98. Mosniam A, Freitag FG, Ignacio R, Salas M, Karoum F, Wolf M et al. Apparent lack of correlation between tyramine and phenylethylamines content and the occurrence of food precipitated migraine. Headache Q 1996; 7:239-49.
99. Shulman KI, Walker SE. Refining the MAOI diet. Tyramine content of pizzas and soy products. J Clin Psychiatr 1999; 60:191-3.
100. Tollefson GD. Monoamine oxidase inhibitors: a review. J Clin Psychiatry 1983; 44:280-8.
101. Clary C, Schweitzer E. The treatment of MAOI hypertensive crisis with sublingual nifedipine. Clin Psychiatry 1987; 48:249-50.
102. Snyder SH, Reynolds IJ. Calcium-antagonist drugs: receptor interactions that clarify therapeutic effects. N Engl J Med 1985; 313:995-1002.
103. Greenberg DA. Calcium channels in neurological disease. Ann Neurol 1997; 42:275-82.
104. 2+ channel function and drug action. Tips 1995; 2:43-49.
105. Wauquier A, Ashton D, Marranes R. The effects of flunarizine in experimental models related to the pathogenesis of migraine. Cephalalgia 1985; 5:119-20.
106. 2+ channel gene CACNLA4. Cell Tiss Res 1996; 87:543-52.
107. Aldeeb SM, Biary N, Bahou Y, Aljaberi M, Khoja W. Flunarizine in migraine: a double-blind placebo-controlled study (in a Saudi population). Headache 1992; 32:461-2.
108. Diamond S, Freitag FG. A double-blind trial of flunarizine in migraine prophylaxis. Headache Q 1993; 4:169-72.
109. Louis P. A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache 1981; 21:235-9.
110. Mendenopoulos G, Manafi T, Logothetis I, Bostantjopoulou S. Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia 1985; 5:31-37.
111. Pini LA, Ferrari A, Guidetti G, Galetti G, Sternieri E. Influence of flunarizine on the altered electronystagmographic (ENG) recordings in migraine. Cephalalgia 1985; 5:173-5.
112. Sorensen PS, Hansen K, Olesen J. A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia 1986; 6:7-14.
113. Thomas M, Behari M, Ahuja GK. Flunarizine in migraine prophylaxis: an Indian trial. Headache 1991; 31:613-5.
114. Frenken CW, Nuijten ST. Flunarizine, a new preventive approach to migraine: a double-blind comparison with placebo. Clin Neurol Neurosurg 1984; 86:17-20.
115. Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci 1992; 19:340-5.
116. Lucking CH, Oestreich W, Schmidt R, Soyka D. Flunarizine vs propranolol in the prophylaxis of migraine: two double-blind comparative studies in more than 400 patients. Cephalalgia 1988; 8:21-26.
117. Grotemeyer KH, Schlake HP, Husstedt IW, Rolf LH. Metoprolol versus flunarizine: a double blind crossover study. Cephalalgia 1987; 7:465-6.
118. Cerbo R, Casacchia M, Formisano R, Feliciani M, Cusimano G, Buzzi MG, Agnoli A. Flunarizine-pizotifen single-dose double-blind cross-over trial in migraine prophylaxis. Cephalalgia 1986; 6:15-18.
119. Louis P, Spierings EL. Comparison of flunarizine (Sibelium) and pizotifen (Sandomigran) in migraine treatment: a double-blind study. Cephalalgia 1982; 2:197-203.
120. Rascol A, Montastruc JL, Rascol O. Flunarizine versus pizotifen: a double-blind study in the prophylaxis of migraine. Headache 1986; 26:83-85.
121. Steardo L, Marano E, Barone P, Denman DW, Monteleone P, Cardone G. Prophylaxis of migraine attacks with a calcium-channel blocker; flunarizine versus methysergide. J Clin Pharmacol 1986; 26:524-8
122. Agnoli A, Bussone G, Mailland F, Manzone GC, Martucci N, Nappi G. Dihydroergokryptine vs flunarizine in the basic treatment of migraine without aura. Cephalalgia 1991; 11:216-7.
123. Ansell E, Fazzone T, Festenstein R, Johnson ES, Thavapalan M, Wilkinson M, Wozniak I. Nimodipine in migraine prophylaxis. Cephalalgia 1988; 8:269-72.
124. Migraine-Nimodipine European Study Group (MINES). European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Headache 1989; 29:633-8.
125. Gelmers HJ. Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. Headache 1983; 23:106-9.
126. Bussone G, Baldini S, D'Andrea G, Cananzi A, Frediani F, Caresia L et al. Nimodipine versus flunarizine in common migraine: a controlled pilot trial. Headache 1987; 27:76-79.
127. Formisano R, Falaschi P, Cerbo R, Proietti A, Catarci T, D'Urso R et al. Nimodipine in migraine: clinical efficacy and endocrinological effects. Eur J Clin Pharmacol 1991; 41:69-71.
128. McArthur JC, Marek K, Pestronk A, McArthur J, Peroutka SJ. Nifedipine in the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side effects. Neurology 1989; 39:284-6.
129. Shukla R, Garg RK, Nag D, Ahuja RC. Nifedipine in migraine and tension headache: a randomized double-blind crossover study. J Assoc Physicians India 1995; 43:770-2.
130. Lamsudin R, Sadjimin T. Comparison of the efficacy between flunarizine and nifedipine in the prophylaxis of migraine. Headache 1993; 33:335-8.
131. Albers GW, Simon LT, Hamik A, Peroutka SJ. Nifedipine versus propranolol for the initial prophylaxis of migraine. Headache 1989; 29:215-8.
132. Markley HG, Cleronis JCD, Piepko RW. Verapamil prophylactic therapy of migraine. Neurology 1984; 34:973-6.
133. Diamond S, Ryan RE, Klapper JA, Goldstein J, Elkind AH, Cady RK et al. Dotarizine in the prophylaxis of migraine headaches. Headache 1999; 39:350.
134. Riopelle R, McCans JL. A pilot study of the calcium channel antagonist diltiazem in migraine syndrome prophylaxis. Can J Neurol Sci 1982; 9:269.
135. Smith R, Schwartz A. Diltiazem prophylaxis in refractory migraine. N Engl J Med 1984; 310:1327-8.
136. Coulam CB, Annagers JR. New anticonvulsants reduce the efficacy of oral contraception. Epilepsia 1979; 20:519-25.
137. Hanston PP, Horn JR. Drug interaction. Newsletter 1985; 5:7-10.
138. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992; 12:81-84.
139. Jensen R, Brinck T, Olesen J. Sodium valproate has prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994; 44:241-4.
140. Klapper JA. An open label crossover comparison of divalproex sodium and propranolol HCl in the prevention of migraine headaches. Headache Q 1995; 5:50-53.
141. Klapper JA. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17:103-8.
142. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52:281-6.
143. Rompel H, Bauermeister PW. Aetiology of migraine and prevention with carbamazepine (Tegretol). S Afr Med J 1970; 44:75-80.
144. Stensrud P, Sjaastad O. Clonazepam (rivotril) in migraine prophylaxis. Headache 1979; 19:333-4.
145. Welch KMA, Chabi E, Bartosh K, Achar VS, Meyer JS. Cerebrospinal fluid gamma aminobutyric acid levels in migraine. Br Med J 1975; 3:516-7.
146. Ferrari MD, Odnik J, Bos KD, Malessy MJA, Bruyn GW. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 1990; 40:1582-6.
147. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura. Neurology 1994; 44:647-51.
148. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997; 54:1141-5.
149. Rall TW, Schleifer LS. Drugs effective in the therapy of epilepsies. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's the pharmacologic basis of therapeutics, 8th edn. New York: Pergamon Press, 1990:436-62.
150. Rimmer EM, Richens A. An update on sodium valproate. Parmacotherapy 1985; 5:171-84.
151. Chapman A, Keane PE, Meldrum BS. Mechanisms of anticonvulsant action of valproate. Prog Neurobiol 1982; 19:315-59.
152. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992; 13:307-11.
153. Behan PO. Prophylactic treatment for migraine: a comparison of pizotifen and clonidine. Cephalalgia 1985; 5:524-5.
154. Freitag FG, Diamond S, Diamond ML, Urban GJ, Pepper B, Moore K. The prophylaxis of migraine with the GABA-agonist, tiagabine: a clinical report. Headache 1999; 19 (Abstract).
155. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study (for the long-term safety of depakote in headache prophylaxis study group). Headache 1999; 39:633-43.
156. Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 1991; 41:961-4.
157. Driefuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Meander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37:379-85.
158. Silberstein SD. Divalproex sodium in headache literature review and clinical guidelines. Headache 1996; 36:547-55.
159. Vainionpaa LK, Rattya J, Knip M, Tapanainen JS, Pakarinen AJ, Lanning P et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999; 45:444-50.
160. Freitag FG, Diamond S, Diamond M, Urban G. Divalproex in the long-term treatment of chronic daily headache. Headache 2001; 41:271-78.
161. Mathew NT. Gabapentin in migraine prophylaxis. Cephalalgia 1996; 16:367.
162. Wessely P, Baumgartner C, Klinger D, Kreczi J, Meyerson N, Sailer L et al. Preliminary results of a double-blind study with the new migraine prophylactic drug Gabapentin. Cephalalgia 1987; 7:477-8.
163. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41:119-28.
164. Streeter AJ, Stahle PL, Hills JF, Lucas PN, McKown LA, Nese SL et al. Pharmacokinetics of topiramate in the rat. Pharm Res 1994; 11:372.
165. Easterling DE, Zakszewski T, Moyer MD. Plasma pharmacokinetics of topiramate, a new anticonvulsant, in humans. Epilepsia 1988; 29:662.
166. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising development stage compounds. Pharmacol Rev 1990; 42:223-86.
167. MacDonald RL, McLean MJ. Anticonvulsant drugs: mechanisms of action. In: Escueta AD, Ward AA, Woodbury DM, Porter RJ, editors. Advances in neurology. New York: Raven Press, 1986:713-36.
168. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000; 41:35-39.
169. Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB et al. Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia 1994; 35:450-60.
170. Edwards KR, Glantz MJ, Shea P, Norton JA, Cross N. A double-blind, randomized trial of topiramate versus placebo in the prophylactic treatment of migraine headache with and without aura. Cephalalgia 2000; 20:316 (Abstract).
171. Potter DL, Hart DE, Calder CS, Storey JR. A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine. Neurology 2000; 54:A15 (Abstract).
172. Brewerton TD, Murphy DL, Mueller EA, Jimerson DC. Induction of migraine like headaches by the serotonin agonist m-chlorophenylpiperazine. Clin Pharmacol Ther 1988; 43:605-9.
173. Gordon ML, Lipton RB, Brown SL, Nakraseive C, Russell M, Pollack SZ et al. Headache and cortical responses to m-chlorophenylpiperazine are highly correlated. Cephalalgia 1993; 13:400-5.
174. Silberstein SD, Fozard JR, Murphy L. Letter to the editor. Headache 1992; 32:242-3.
175. 2 receptor subtypes: a family reunited. Tips 1995; 16:105-10.
176. Fozard JR, Kalkman HO. 5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives. Arch Pharmacol 1994; 350:225-9.
177. 2c receptor blockade? Life Sci 1999; 54:641-4.
178. Fozard JR. The 5-hydroxytryptamine-nitric oxide connection: the key link in the initialization of migraine? Arch Int Pharmacodyn 1995; 329:111-9.
179. Moskowitz MA. Interpreting vessel diameter changes in vascular headaches. Cephalalgia 1992; 12:5-7.
180. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Tips 1992; 13:307-11.
181. Wei EP, Moskowitz MA, Boccalini P, Kontos HA. Calcitonin gene-related peptide mediates nitroglycerine and sodium nitroprusside-induced vasodilation in feline cerebral arterioles. Circ Res 1992; 70:1313-9.
182. Fozard JR. 5-HT in migraine: evidence from 5-Ht receptor antagonists for a neuronal etiology. In: Sandler M, Collins GM, editors. Migraine: a spectrum of ideas. New York: Oxford University Press, 1990:128-46.
183. Nelson DL. Proceedings from the International Business Communications Conference on serotonin receptors in the central nervous system, January 25-26, 1996.
184. Muller SE. Ergot alkaloids in migraine: is the effect via 5-HT receptors. In: Olesen J, Saxena PR, editors. 5-Hydroxytryptamine mechanisms in primary headaches. New York: Raven Press, 1992:297-304.
185. 3H-spiroperidol. Mol Pharmacol 1979; 16:687-9.
186. 1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol 1991; 102:323-30.
187. 1-like receptors. Br J Pharmacol 1991; 104:183-9.
188. MacLennan SJ, Martin GR. Comparison of the effects of methysergide and methylergometrine with GR 43175 on feline carotid blood flow distribution. Br J Pharmacol 1990; 99:221.
189. Saito K, Markowtiz S, Moskowitz MA. Ergot alkaloids specifically block the development of neurogenic inflammation within the dura mater induced by chemical or electrical stimulation. Ann Neurol 1988; 24:732-7.
190. Sicuteri R. Prophylactic and therapeutic properties of 1-methylsergic acid butanolamide in migraine. Int Arch Allerg 1959; 15:300-7.
191. Graham JR, Suby HI, LeCompte PR, Sadowsky NL. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 1966; 274:360-8.
192. Behan PO, Reid M. Propranolol in the treatment of migraine. Practitioner 1980; 224:201-4.
193. Barrie MA, Fox WR, Weatherall M, Wilkinson MIP. Analysis of symptoms of patients with headaches and their response to treatment with ergot derivatives. Q J Med 1968; 146:319-36.
194. Andersson PG. BC105 and deseril in migraine prophylaxis: a double-blind study. Headache 1973; 13:68-73.
195. Cangi F, Boccuni M, Zanotti A, Mailland F, Sicuteri F. Dihydroergokryptine (DEK) in migraine prophylaxis in a double-blind study vs methysergide. Cephalalgia 1989; 9:448-9.
196. Forssman B, Henriksson KG, Kihlstrand S. A comparison between BC105 and methysergide in the prophylaxis of migraine. Acta Neurol Scand 1972; 48:204-12.
197. Hudgson P, Foster JB, Newell DJ. Controlled trial of demigran in the prophylaxis of migraine. Br Med J 1967; 2:91-93.
198. Lance JW, Fine RD, Curran DA. An evaluation of methysergide in the prevention of migraine and other vascular headaches. Med J Aust 1963; 1:814-8.
199. Pedersen E, Moller CE. Methysergide in migraine prophylaxis. Pharmacol Ther 1966; 7:520-6.
200. Presthus J. BC105 and methysergide (Deseril) in migraine prophylaxis. Acta Neurol Scan 1971; 47:514-8.
201. Ryan RE. Double-blind crossover comparison of BC105, methysergide, and placebo in the prophylaxis of migraine headache. Headache 1968; 8:118-26.
202. Shekelle RB, Ostfeld AM. Methysergide in the migraine syndrome. Clin Pharmacol Ther 1964; 5:201-4.
203. Sicuteri F. The ingestion of serotonin precursors (L-5-hydroxytryptophan and L-tryptophan) improves migraine headache. Headache 1973; 13:19-22.
204. Curran DA, Hinterberger H, Lance JW. Methysergide. Res Clin Stud Headache 1967; 1:74-122.
205. Curran DA, Lance JW. Clinical trial of methysergide and other preparations in the management of migraine. J Neurol Neurosurg Psychiatry 1964; 27:463-9.
206. Graham J. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci 1967; 254:1-12.
207. Elkind AH, Friedman AP, Bachman A, Siegelman SS, Sacks OW. Silent retroperitoneal fibrosis associated with methysergide therapy. JAMA 1968; 206:1041-4.
208. Raskin NH. Headache, 2nd edn. New York: Churchill-Livingstone, 1988.
209. Bana DS, MacNeal PS, LeCompte PM, Shah Y, Graham JR. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 1974; 88:640-55.
210. Barlow CF. Headaches and migraine in children. Philadelphia: JB Lipincott, 1984.
211. Forsythe I, Hockaday JM. Management of childhood migraine. In: Hockaday JM, editor. Migraine in childhood. London: Butterworths, 1988:63-74.
212. Smyth GA, Lazarus L. Suppression of growth hormone secretion by melatonin and cyproheptadine. J Clin Invest 1974; 54:116-21.
213. Bellavance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline, and palcebo in migraine prophylaxis. Headache 1990; 30:710-5.
214. Arthur GP, Hornabrook RW. The treatment of migraine with BC105 (pizotifen): a double-blind trial. N Z Med J 1971; 73:5-9.
215. Carroll JD, Maclay WP. Pizotifen (BC105) in migraine prophylaxis. Curr Med Res Opin 1975; 3:68-71.
216. Hughes RC, Foster JB. BC 105 in the prophylaxis of migraine. Curr Ther Res Clin Exp 1971; 13:63-68.
217. Krakowski AJ, Engisch R. A new agent for chemotherapy of migraine headaches: a controlled study. Psychosomatics 1973; 14:302-8.
218. Lance JW, Anthony M. Clinical trial of a new serotonin antagonist, BC105, in the prevention of migraine. Med J Aust 1968; 1:54-55.
219. Lawrence ER, Hossain M, Littlestone W. Sanomigran for migraine prophylaxis: controlled multicenter trial in general practice. Headache 1977; 17:109-12.
220. Osterman PO. A comparison between placebo, pizotifen, and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol (Divascan) in migraine prophylaxis. Acta Neurol Scand 1977; 56:17-28.
221. Ryan RE. BC105, a new preparation for the interval treatment of migraine: a double blind evaluation compared with placebo. Headache 1971; 11:6-18.
222. Sjaastad O, Stensrud P. Appraisal of BC105 in migraine prophylaxis. Acta Neurol Scand 1969; 45:594-600.
223. Nappi G, Sandrini G, Savoini G, Cavallini A, DeRysky C, Micieli G. Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine. Drugs 1987; 33:103-98.
224. Gawel M. A double blind, cross over study of nimodipine versus pizotyline in common and classical migraine. Cephalalgia 1987; 7:453-4.
225. Kangasniemi P. 1-isopropylnoradrenochrome-5-monosemicarbazono, and pizotifen in migraine prophylaxis. Headache 1979; 19:219-22.
226. Nattero G, Biale L, Savi L. Lisuride and pizotifen in the treatment of migraine without aura. Cephalalgia 1991; 11:218-9.
227. Bono G, Criscuoli M, Martignoni E, Salmon S, Nappi G. Serotonin precursors in migraine prophylaxis. Adv Neurol 1982; 33:357-63.
228. Havanka-Kanniainen H, Hokkanen E, Myllyla VV. Efficacy of nimodipine in comparison with pizotifen in the prophylaxis of migraine. Cephalalgia 1987; 7:7-13.
229. Micieli G, Trucco M, Agostinis C, Mancuso A, Papalia F, Sinforiani E et al. Nimodipine vs pizotifen in common migraine: results of a double-blind crossover trial. Cephalalgia 1985; 5:532-3.
230. Hubbe P. The prophylactic treatment of migraine with an antiserotonin pizotifen. Acta Neurol Scand 1973; 49:108-14.
231. Peatfield R. Drugs acting by modification of serotonin function. Headache 1986; 26:129-31.
232. Capildeo R, Rose FC. Single-dose pizotifen, 1.5 mg nocte: a new approach in the prophylaxis of migraine. Headache 1982; 22:272-5.
233. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J 1985; 291:569-73.
234. Murphy JJ, Heptinstall S, Mitchell JR. Randomized double-blind placebo controlled trial of feverfew in migraine prevention. Lancet 1988; 2:189-92.
235. Palevitch D, Earon G, Carusso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res 1997; 11:508-11.
236. Deweerdt CJ, Bootsma HP, Hendriks H. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of feverfew preparation. Phytomedicine 1996; 3:225-30.
237. Heptinstall S, White A, Williamson L, Mitchel JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leukocytes. Lancet 1985; i:1071-4.
238. Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behavior via neutralization of sulphydryl groups. J Pharm Pharmacol 1987; 39:459-65.
239. Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998; 18:704-8.
240. 31phosphorus NMR spectroscopy. Neurology 1989; 39:538-41.
241. 31P-Magnetic resonance spectroscopy in migraine without aura. Neurology 1994; 44:666-9.
242. Sangiorgi S, Mochi M, Riva R, Cortelli P, Monari L, Pierangeli G, Montagna P. Abnormal platelet mitochondrial function in patients affected by migraine with and without aura. Cephalalgia 1994; 14:21-23.
243. 1H-magnetic resonance spectroscopy in migraine during the interictal period. Neurology 1996; 47:1093-5.
244. Arts WF, Scholte HR, Boggard JM, Kerrebijn KF, Luyt-Housen IE. NADH-CoQ reductase deficient myopathy: successful treatment with riboflavin. Lancet 1983; 2:581-2.
245. 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992; 42:2147-52.
246. Antozzi C, Garavaglia B, Mora M, Rimoldi M, Morandi L, Ursino E, DiDonato S. Late-onset riboflavin-responsive myopathy with combined multiple acyl coenzyme. A dehydrogenase and respiratory chain deficiency. Neurology 1994; 44:2153-8.
247. Scholte HR, Busch HF, Bakker HD, Bogaard JM, Luyt-Houwen IE, Kuyt LP. Riboflavin-responsive complex I deficiency. Biochimica Biophysica Acta 1995; 1271:75-83.
248. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50:466-70.
249. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multicenter, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16:257-63.
250. Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH et al. Magnesium in the prophylaxis of migraine - a double-blind, placebo-controlled study. Cephalalgia 1996; 16:436-40.
251. O'Neill BP, Mann JD. Aspirin prophylaxis in migraine. Lancet 1979; 2:1179-81.
252. Masel BE, Chesson AL, Peters BH, Levin HS, Alperin JB. Platelet antagonists in migraine prophylaxis: a clinical trial using aspirin and dipyridamole. Headache 1980; 20:13-18.
253. Peto R, Gray R, Collins R, Wheatly K, Hennekens C, Jamrozik K. Randomized trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296:313-6.
254. Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA 1990; 264:1711-3.
255. Baldratti A, Cortelli P, Proccaccianti G, Gamberini GD, D'Allessandro R, Baruzzi A, Sacquegna T. Propranolol and acetylsalicylic acid in migraine prophylaxis. Double-blind crossover study. Acta Neurol Scand 1983; 67:181-6.
256. Pradalier A, Clapin A, Dry J. Treatment review: nonsteroid antiinflammatory drugs in the treatment and long-term prevention of migraine attacks. Headache 1988; 28:550-7.
257. Sjaastad O, Spierings EL. Hemicrania continua: another headache absolutely responsive to indomethacin. Cephalalgia 1984; 4:65-70.
258. Sjaastad O, Dale I. A new (?) clinical headache entity: chronic paroxysmal hemicrania. 2. Acta Neurol Scand 1976; 54:140-59.
259. Bordini C, Antonaci F, Stovner LJ, Schrader H, Sjaastad O. 'Hemicrania Continua' - a clinical review. Headache 1991; 31:20-26.
260. Feldman MH, Schlezinger NS. Benign intracranial hypertension associated with hypervitaminosis A. Arch Neurol 1970; 22:1-7.
261. Adam EI, Gore SM, Price WH. Double-blind trial of clonidien in the treatment of migraine in a general practice. J R Coll Gen Pract 1978; 28:587-90.
262. Boisen E, Deth S, Hubbe P, Jansen J, Klee A, Leunbach G. Clonidine in the prophylaxis of migraine. Acta Neurol Scand 1978; 58:288-95.
263. Bredfeldt RC, Sutherland JE, Kruse JE. Efficacy of transdermal clonidine for headache prophylaxis and reduction of narcotic use in migraine patients. A randomized crossover trial. J Fam Pract 1989; 29:153-6.
264. Das SM, Ahuja GK, Narainaswamy AS. Clonidine in prophylaxis of migraine. Acta Neurol Scand 1979; 60:214-7.
265. Kallanranta T, Hakkarainen H, Hokkanen E, Tuovinen T. Clonidine in migraine prophylaxis. Headache 1977; 17:169-72.
266. Mondrup K, Moller CE. Prophylactic treatment of migraine with clonidine: a controlled clinical trial. Acta Neurol Scand 1977; 56:405-12.
267. Ryan RE Sr, Ryan RE Jr. The effects of clonidine in the prophylactic treatment of migraine. Headache 1975; 15:199-212.
268. Shafar J, Tallett ER, Knowlson PA. Evaluation of clonidine in prophylaxis of migraine. Double-blind trial and followup. Lancet 1972; 1:403-7.
269. Sjaastad O, Stensrud P. 2-(2.6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155 or Catapresan) as a prophylactic remedy against migraine. Acta Neurol Scand 1971; 47:120-2.
270. Stensrud P, Sjaastad O. Clonidine (Catapresan)-double-blind study after long-term treatment with the drug in migraine. Acta Neurol Scand 1976; 53:233-6.
271. Wilkinson M. Preliminary report on the use of clonidine (Boehringer Ingelheim) in the treatment of migraine. Res Clin Stud Headache 1970; 3:315-20.
272. Elkind AH, Webster C, Herbertson RK. Efficacy of guanfacine in a double-blind parallel study for migraine prophylaxis. Cephalalgia 1989; 9:369-70.
273. Louis P, Schoenen J, Hedman C. Metoprolol vs clonidine in the prophylactic treatment of migraine. Cephalalgia 1985; 5:159-65.
274. Kass B, Nestvold K. Propranolol (Inderal) and clonidine (Catapressan) in the prophylactic treatment of migraine: a comparative trial. Acta Neurol Scand 1980; 61:351-6.
275. Anthony M, Lance JW, Somerville B. A comparative trial of prindolol, clonidine and carbamazepine in the interval therapy of migraine. Med J Aust 1972; 6:1343-6.
276. Silberstein SD, Mathew N, Saper J, Jenkin S. Botulinum toxin type A as a migraine preventive treatment: for the Botox® Migraine Clinical Research Group. Headache 2000; 40:445-50.
277. Silberstein SD, Lipton RB, Goadsby PJ. Migraine: diagnosis and treatment. In: Silberstein SD, Lipton RB, Goadsby PJ, editors. Headache in clinical practice, 1st edn. Oxford: Isis Medical Media Ltd., 1998:61-90.
278. Silberstein SD. Preventive treatment of migraine: an overview. Cephalalgia 1997; 17:67-72.
279. Solomon GD. Management of the headache patient with medical illness. Clin J Pain 1989; 5:95-99.
280. Silberstein SD, Lipton RB, Breslau N. Migraine: association with personality characteristics and psychopathology. Cephalalgia 1995; 15:337-69.
281. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S et al. Prophylaxis of migraine headaches with divalproex sodium. Arch Neurol 1995; 52:281-6.
282. Bowden CL, Brugger AM, Swann AC. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271:918-24.